Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | RORA | P35398 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.53 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.51 |
| ▸ | EDNRB | P24530 | 2/20 | 0.49 |
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812673 | 0.88 | TSHR (0.74) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL31110643 | 0.88 | TSHR (0.74) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL5044548 | 0.84 | TSHR (0.55) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL9478942 | 0.82 | TSHR (0.71) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL3261087 | 0.82 | TSHR (0.71) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL6409546 | 0.82 | TSHR (0.67) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL16785737 | 0.82 | TSHR (0.67) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL15762086 | 0.78 | TSHR (1.00) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL12793716 | 0.78 | ALDH1A1 (0.65) | TSHRPGRRORARORCNR1H2 | |
| SCHEMBL8752480 | 0.78 | PGR (0.74) | TSHRPGRRORARORCNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-1250325-B1 | PHENANTHRIDINE-N-OXIDES | NYCOMED GMBH (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-6630483-B2 | Phenanthridine-N-oxides | ALTANA PHARMA AG (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | TSHR 183/4885PGR 1707/4885RORA 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.